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resource – NHS Blood and Transplant currently charges £122 
for each unit of blood, to which the cost of transfusion staff 
time, equipment and consumables must be added. 
Over and above these concerns, retrospective studies have 
suggested that early transfusion is associated with a substantially 
increased risk of re-bleeding and consequent mortality in patients 
with AUGIH.2,4,9 Caution is required in the interpretation of these 
findings because bleed severity is a major potential confounding 
factor – patients with severe bleeds are inherently more likely to 
receive both a blood transfusion and have an adverse outcome. 
However, two randomised controlled trials now support the 
suspicion of a causal relationship between transfusion and 
outcome, by providing strong evidence that a restrictive blood 
transfusion policy improves the prognosis in severe AUGIH.10,11 
This finding leads to the concept of ‘overtransfusion’, a 
situation where blood is administered in excess of requirements, 
with the immediate potential for deleterious effects.12 
There is no agreed definition, but taking a post-transfusion 
haemoglobin concentration ([Hb]) of greater than 100 g/L as 
an arbitrary marker, in-house audits in 2008 and 2011 revealed 
that overtransfusion was commonplace – about 50% of subjects 
with AUGIH given blood had a post-transfusion [Hb] of over 
100 g/L, and in 16% it exceeded 120 g/L. 
The post-transfusion [Hb] only allows overtransfusion to 
be identified in retrospect, when it is too late to intervene. 
However, the audits suggested that a high pre-transfusion 
[Hb] and a cross-match request for a large number of units 
were both major predictors of subsequent overtransfusion. 
As a first step towards attempting to address the issue of 
overtransfusion, the Gastroenterology Department at Poole 
Hospital introduced guidelines for blood use in patients with 
AUGIH in the form of a simple table as outlined below. This 
study describes the impact of these guidelines.
Method
A simple cross-match policy was devised aiming to limit the 
number of units initially provided for patients with AUGIH 
according to the pre-transfusion [Hb] and presence or absence 
of shock and/or suspected varices (Table 1). The target in 
patients transfused was a post-transfusion [Hb] in the range 
90–100 g/L. Overtransfusion was arbitrarily defined as a 
post-transfusion [Hb] exceeding 100 g/L, while figures of over 
110 g/L were considered to indicate major overtransfusion.
Blood transfusion is widely used in the management of acute 
upper gastrointestinal haemorrhage (AUGIH). Trial data 
suggests that excessive transfusion may be detrimental, yet 
overtransfusion remains commonplace. This study reports the 
impact of introducing a simple cross-match policy in a district 
general hospital, which resulted in a substantial fall in the 
prevalence of overtransfusion (odds ratio 0.43; 95% conﬁdence 
interval 0.19–0.98), with potential patient beneﬁts in terms of 
rebleeding, and a reduction in the total blood transfused from 
162 to 121 units per 100 patients with AUGIH. For the cost of 
blood alone, this corresponds to projected savings across the 
NHS in England in excess of £2 million per annum.  
KEYWORDS: Acute upper gastrointestinal haemorrhage, blood 
transfusion, overtransfusion
Introduction
Acute upper gastrointestinal haemorrhage (AUGIH) is a 
common and potentially serious medical emergency, with 
an incidence of about 1 per 1,000 population per annum, 
and a 28-day mortality of 8–10%.1–3 While bleeding ceases 
spontaneously in the majority, rebleeding occurs in 10–15% of 
cases despite pharmacological and/or endoscopic intervention.2,4 
Rebleeding is a major predictor of poor prognosis in AUGIH.5
A recent UK national audit revealed that 44% of individuals 
with AUGIH receive a blood transfusion within 12 hours of 
admission,6 and it is estimated that 14% of all blood used 
in the UK is for the treatment of gastrointestinal bleeding.7 
Transfusion seems an intuitive aspect of management, and 
in the exsanguinating patient it may be lifesaving, however 
this is a relatively uncommon situation. On the other hand, 
there are already many reasons for caution in the use of blood 
transfusion, including the risk of immunological, infective and 
metabolic complications.8 Furthermore, blood is a valuable 
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After discussion, refinement and a period of staff education, 
the policy was introduced in Poole Hospital in June 2012. 
The guidelines were ‘policed’ by the biomedical scientist on 
shift, with the option of involvement of the on-call consultant 
endoscopist if an agreement could not be reached with the 
requesting clinician. Clinicians were free to request more blood 
at a later date if required, in particular due to a falling [Hb] 
resulting from ongoing bleeding.
Anonymised demographic and clinical data were collected 
retrospectively for all patients referred for endoscopy at Poole 
Hospital with suspected AUGIH during two six-month periods, 
the first before (July to December 2011 – group 1) and the 
second after (July to December 2012 – group 2) introduction 
of the policy. Exclusion criteria were (1) lack of confirmation 
of an acute bleed, (2) inadequate clinical information and (3) 
extreme case complexity. 
The number of units cross-matched and transfused was 
assessed from hospital records and confirmed using the 
transfusion laboratory computer system, which records the fate 
of each unit of blood. This enabled identification of the exact 
date and time that the blood was transfused so that [Hb] results 
before and after transfusion could be identified. This was 
especially useful in those situations where a patient had a cross-
match requested, but was not transfused until a later date. In 
situations where a patient required more than one transfusion, 
only the first episode was recorded. 
Statistical analyses were undertaken to assess (1) the effect of 
the cross-match guidelines on blood usage and the proportion 
of patients overtransfused, (2) compliance with the cross-match 
policy guidelines for AUGIH and (3) clinical factors predictive of 
overtransfusion in both cohorts. Specifically, comparisons were 
made between the two patient groups in terms of their baseline 
characteristics and the different outcome measures. Continuous 
data were summarised using the mean with 95% confidence 
intervals (CIs) or median with interquartile range, and 
compared using either a t-test or rank-sum test (depending on 
the probability distribution of the data). Categorical data were 
presented as proportions and the groups compared using the 
Pearson χ2 and, where appropriate, odds ratios with 95% CIs. 
Multiple logistic regression analysis was used to assess 
the patient characteristics and clinical factors that might 
predict the odds of overtransfusion. Regression models were 
developed iteratively using least squares approach and assessed 
through analysis of variance and residual plots to provide an 
appropriately specified and parsimonious model. All analyses 
were undertaken using STATA software (version 13.1). Data 
were not available for every variable for all patients, and these 
observations were excluded from the subsequent analyses that 
included the particular variable.
Results
A total of 245 subjects were initially identified. Exclusions were 
made as follows: AUGIH not confirmed on review (11 cases); 
clinical information inadequate (7 cases); and clinical 
complexity (1 case). This left 122 subjects for analysis in group 
1 and 105 in group 2. There were no significant differences 
between the two groups in age, sex ratio, [Hb] at presentation 
or Rockall score (Table 2). 
A total of 259 units and 148 units were cross-matched for 
the patients in groups 1 and 2 respectively, representing a 43% 
reduction. Following on from this, a total of 198 units and 
127 units were transfused, a 36% reduction. The reduction in 
Table 1. Poole cross-match policy guidelines. 
Pre-transfusion 
[Hb], g/L
Units for cross-match
Not shocked and 
varices not suspected
Shocked and/or 
varices suspected
≥100 0 0
90–9 0 2
80–9 (1)a 3
70–9 2 4
60–9 3 5
<60 4 6
aIf a one unit transfusion felt to be justified. [Hb] = haemoglobin concentration.
Table 2. Comparison of the baseline characteristics of the two patient cohorts. 
Baseline characteristics Group 1 (2011) Group 2 (2012) p value
Total in group 131 114 –
Included in analysis 122 105 –
Median age (IQR), years 78 (66–85) 75 (66–84) 0.45
Male 57% 50% 0.29
Confirmed varices 7% 9% –
Median presentation [Hb] (IQR), g/L 96 (73–121) 92 (72–124) 0.89
Rockall score
0–1 5% 8% 0.18
2–3 26% 27%
4–5 41% 47%
6–7 25% 14%
8+ 3% 4%
[Hb] = haemoglobin concentration; IQR = interquartile range.
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blood transfused was due to the combination of (1) a slight 
disparity between the number of subjects in each group (122 vs 
105), (2) a reduction in the proportion of patients transfused 
(58% vs 50%; χ2=1.36, p=0.24), and (3) a reduction in the 
number of units administered to each recipient of blood (mean 
2.8 vs 2.4; t-test 1.95, p=0.05). The data are shown in Table 3. 
Using the definitions given in the method section, the 
proportion of patients overtransfused (as a percentage of 
those transfused) decreased from 48% in group 1 to 28% in 
group 2. This was primarily due to a significant reduction in 
the proportion receiving a major overtransfusion (>110 g/L), 
which fell from 22% to 8% (Table 4). Logistic regression 
analysis of combined data from the two cohorts confirmed 
that ‘initial [Hb]’ and ‘units transfused’ were the two major 
independent clinical variables predictive of overtransfusion 
– with odds ratios (95% CI) of 1.10 (1.04–1.16) and 2.87 
(1.61–5.11) respectively. 
Compliance with the guidelines was assessed for group 2, and 
compared with the theoretical compliance for group 1, had the 
guidelines existed in 2011. There was a significant reduction in 
the proportion of non-compliant cases from 37% in group 1 
to 22% in group 2, primarily due to a fall in the prevalence of 
more profound non-compliance (Table 5).
Data for length of stay, rebleeding and 28-day mortality 
are shown in Table 6. As anticipated, blood transfusion was 
associated with longer lengths of stay, and increased risks 
of rebleeding and death. However, it is important to stress 
that the study was not powered to detect differences in these 
outcome parameters between the two groups, and that the 
differences were not statistically significant. Furthermore, 
the retrospective study design is likely to result in an 
underestimate of rebleeding rates. 
At Poole Hospital, the Departments of Medicine and Elderly 
Care manage patients with AUGIH. Independent data from 
the Transfusion Service were used to assess the impact of the 
cross-match policy by comparing the total quantity of blood 
transfused for all indications by these two departments for the 
2 years before and after introduction (Fig 1). The figure fell 
from a mean of 91.1 units transfused per month for July 2010 
to June 2012, to a mean of 70.2 units per month for July 2012 to 
June 2014 (t-test 4.25, p=0.01). 
Conclusion
The link between rebleeding and the increased risk of 
morbidity and mortality in AUGIH is well established. This 
has rightly resulted in increasing emphasis on active measures 
to achieve stable haemostasis in AUGIH over recent years 
by means of pharmacological, endoscopic and radiological 
interventions.3,13,14 Nevertheless, blood transfusion has been an 
integral component of the management of AUGIH for decades, 
on the grounds that it would seem logical to replace the body 
fluid lost on a like for like basis. 
However, two randomised controlled trials have concluded 
that excessive transfusion may actually be detrimental in severe 
AUGIH, in particular by predisposing to rebleeding. In the first 
of these,10 a small study, the rebleed rate was 9/24 (37.5%) in the 
group receiving at least 2 units of blood in the first 24 hours, 
but just 1/26 (3.8%) in the group restricted to transfusion only 
if profoundly anaemic or shocked (p<0.01). A difference in 
rebleed rates was confirmed in the second study.11 This had 
sufficient power to allow a comparison of 45-day mortality 
rates between groups allocated to a liberal strategy (transfusion 
when [Hb] below 90 g/L) or a restrictive strategy (transfusion 
when [Hb] below 70 g/L) – with figures of 41/445 (9.2%) and 
23/444 (5.2 %) respectively (p<0.02). 
Table 3. The usage of blood in each cohort.
Characteristics Group 1 
(2011)
Group 2 
(2012)
Cases analysed 122 105
Units cross-matched in total 259 148
Units transfused in total 198 127
Cross-matched, % (n) 64 (78) 51 (54)
Units cross-matched per patient, n 3.3 (259/78) 2.7 (148/54)
Transfused, % (n) 58 (71) 50 (53)
Transfused, n 2.8 (198/71) 2.4 (127/53) 0
100
200
300
400
500
600
2010 (2) 2011 (1) 2011 (2) 2012 (1) 2012 (2) 2013 (1) 2013 (2) 2014 (1)
Six-month me periods
To
ta
l b
lo
od
 u
sa
ge
 in
 
m
e
pe
rio
d/
un
its
   
Fig 1. Total blood usage in the Departments of Medicine and Elderly 
Care, Poole Hospital 2010–2014. Grey arrow shows the point of introduction 
of the cross-match policy in 2012.
Table 4. Overtransfusion in each group (see text for definitions).
Post-transfusion [Hb] Group 1 (2011), % (n) Group 2 (2012), % (n) OR (95% CI)
>100  g/L 48 (33/69a) 28 (15/53) 0.43 (0.19–0.98)
>110 g/L 22 (15/69a) 8 (4/53) 0.29 (0.07–1.02)
aTwo subjects in group 1 had no recorded post-transfusion [Hb], and could not be assessed for overtransfusion. CI = confidence interval; [Hb] = haemoglobin 
concentration; OR = odds ratio.
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These observations are at first sight counterintuitive, but studies 
of acute haemorrhage in human trauma15 and experimental 
animals16 have revealed comparable findings, and provided some 
insight into the pathophysiological basis for it. In essence, the 
adaptive response to acute haemorrhage from any source involves 
a number of mechanisms directed towards minimising blood 
loss, including the development of hypotension, vasoconstriction 
and a hypercoagulable state. In evolutionary terms this 
presumably conveys survival advantage. Blood transfusion 
opposes all of these changes,15,16 and it is likely that the same 
applies to bleeding in the specific context of AUGIH.10
The trial findings suggest that the relationship between post-
transfusion [Hb] and the probability of an adverse outcome in 
severe AUGIH may be a U-shaped curve with undertransfusion 
potentially leading to an increased risk of cardiovascular 
complications, and excessive transfusion resulting in an 
increased likelihood of rebleeding. This introduces the concept 
of ‘overtransfusion’. While the optimal post-transfusion [Hb] 
may of course vary depending on other clinical factors, trial 
data10,11 and national guidelines3,13 would suggest that is likely 
to be in the range 70–90 g/L. 
Overtransfusion is not only potentially detrimental for the 
reasons outlined above, but also clearly wasteful of a valuable 
resource. Our study suggests that the introduction of a simple 
cross-match policy can curb the risk of overtransfusion, with 
a reduction in the transfusion rate from 162 to 121 units per 
100 patients with AUGIH. A typical District General Hospital 
managing 250 cases a year could therefore potentially save 
£12,000 pa on blood alone – if applied across the NHS in 
England this equates to over £2 million pa. In addition, one 
might anticipate considerable indirect cost savings from a 
reduction in the interventions and extended lengths of stay 
required to address rebleeding episodes. 
There may be a number of reasons why overtransfusion 
is so common. First, transfusion to achieve a haemoglobin 
level of over 100 g/L has been standard medical practice for 
decades, so it is likely to take a while to alter this mindset. 
Second, quantifying blood loss at the bedside can be difficult, 
and there is an understandable tendency to err on the side 
of ‘caution’, with allowance made for fluid re-equilibriation. 
Third, decisions regarding cross-matching and transfusion 
are often made by relatively inexperienced junior medical 
staff, sometimes in emotionally charged situations. Finally, we 
are not aware of any other specific cross-matching guidelines 
for AUGIH, either published or in use in UK hospitals, and 
contemporary national and international guidelines on this 
topic are worded in somewhat vague terms.3,13,14 The 2007 
countrywide audit6 confirmed that the use of blood for AUGIH 
at Poole Hospital adjusted for bleed severity was close to the 
national average, indicating that our findings are likely to be a 
fair reflection of the national pattern of blood usage. 
Our results may have underestimated the potential savings from 
a cross-match policy for two particular reasons. First, compliance 
with the guidelines in group 2 was not perfect. Individual 
case investigations are underway to establish the reasons for 
this, and it may be that in some cases there were extenuating 
circumstances. Equally, with ongoing education it may be that 
compliance – and therefore savings – can be improved further. 
Second, to avoid any possibility that our patients might end up 
being undertransfused, we chose thresholds for the cross-match 
policy and the definition of overtransfusion on the basis of trial 
results10,11 and national guidelines3,13 could be deemed generously 
high. With further experience and consensus, it is likely that both 
could be safely lowered. 
Many other factors may of course have contributed to the 
fall in departmental blood usage for all indications shown in 
Fig 1. Nevertheless the step-wise reduction in usage at the time 
of introduction of our cross-match policy is quite striking. 
Interestingly, the mean reduction of just over 20 units per 
month is rather larger than the fall of approximately 12 units 
per month that we would have predicted from the results of 
the study. This may simply reflect the influence of unrelated 
initiatives,17 but an alternative interpretation could be that the 
introduction of our specific cross-match policy for AUGIH 
encouraged medical staff to adopt a more conservative 
approach to transfusion in other clinical circumstances. 
It is important to highlight that the study reported here is 
observational, and not a randomised controlled trial. We did 
Table 5. Non-compliance with the cross-match policy.
Outside guidelines Group 1 (2011),  % (n) Group 2  (2012), % (n) OR (95% CI)
By ≥1 units 37 (45/122) 22 (23/105) 0.47 (0.24–0.89)
By ≥2 units 27 (33/122) 10 (11/105) 0.32 (0.14–0.69)
CI = confidence interval; OR = odds ratio.
Table 6. Outcome parameters.
Group Transfused? n Median LoS (IQR), days Rebleed (%) 28-day mortality (%)
Group 1 (2011) No 51 3 (2–5) 0 (0.0) 2 (3.9)
Yes 71 8 (4–13) 3 (5.6) 10 (14.1)
Group 2 (2012) No 52 2 (1–5) 1 (1.9) 1 (1.9)
Yes 53 10 (5–15) 3 (5.7) 5 (9.4)
IQR = interquartile range; LoS = length of stay.
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our best to minimise other influences, for example by using 
the same calendar months for each cohort to control for the 
effect of junior doctor experience, and concluding the second 
study period just before the month of publication of the seminal 
NEJM paper.11 We cannot however exclude the possibility that 
external factors may have influenced the results, notably the 
drive towards more appropriate use of blood transfusion.17 
It was an unfortunate coincidence that the NICE guidelines 
for management of acute upper GI bleed 14 were published 
in the same month as we introduced our cross-match policy. 
However, we feel that these weighty guidelines are unlikely 
to have influenced our results, as the advice regarding blood 
transfusion simply encourages clinicians to ‘base decisions on 
blood transfusion on the full clinical picture, recognising that 
overtransfusion may be as damaging as undertransfusion’.14
In conclusion, we have demonstrated that introducing a 
simple cross-match policy for AUGIH can considerably reduce 
the usage of blood for this indication and the prevalence of 
overtransfusion. On the basis of published trial data, further 
patient benefits and savings would be anticipated as the result 
of a reduced risk of rebleeding. We would encourage other units 
to trial the cross-match policy and publish their prospective 
analysis of the outcome. ■
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